Distintos derivados de antraciclina para la reducción de la cardiotoxicidad en pacientes con cáncer
Información
- DOI:
- https://doi.org/10.1002/14651858.CD005006.pub2Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 18 octubre 2006see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Review
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Cáncer ginecológico, neurooncología y otros cánceres
- Copyright:
-
- Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
Elvira van Dalen designed the study and wrote the review. She developed the search strategy and undertook the searches. She searched for unpublished and ongoing studies and identified the studies meeting the inclusion criteria. She performed the data‐extraction and quality assessment of the included studies. She analyzed the data and interpreted the results. She wrote and revised the manuscript.
Erna Michiels identified the studies meeting the inclusion criteria. She performed the data‐extraction and quality assessment of the included studies. She critically reviewed the manuscript.
Huib Caron critically reviewed the review. He contributed to the data‐analysis and the interpretation of the results. He critically reviewed the manuscript.
Leontien Kremer designed the study and critically reviewed the review. She performed the data‐extraction and quality assessment of the included studies. She contributed to the data‐analysis and the interpretation of the results. She critically reviewed the manuscript.
All authors approved the final version.
Sources of support
Internal sources
-
Dutch Cochrane Centre, Netherlands.
External sources
-
Foundation of Pediatric Cancer Research (SKK) Amsterdam, Netherlands.
Declaraciones de interés
Desconocidos
Agradecimientos
Se agradece a Heleen van der Pal por su ayuda en la preparación del protocolo de esta revisión. También se agradece a Leon Bax por traducir los artículos en japonés. Finalmente, se agradece a los financiadores por el apoyo económico que permitió realizar esta revisión sistemática.
Para la comparación de epirrubicina versus doxorrubicina, el cociente de riesgos instantáneos y las estadísticas asociadas se calcularon mediante una hoja de cálculo de Excel desarrollada por Matthew Sydes (Cancer Division) en colaboración con el Meta‐analysis Group of the MRC Clinical Trials Unit, Londres.
Para la comparación de doxorrubicina y doxorrubicina encapsulada en liposomas, el cociente de riesgos instantáneos y las estadísticas asociadas se calcularon mediante una hoja de cálculo de Excel proporcionada por Heather Dickinson.
Version history
| Published | Title | Stage | Authors | Version |
| 2010 May 12 | Different anthracycline derivates for reducing cardiotoxicity in cancer patients | Review | Elvira C van Dalen, Erna MC Michiels, Huib N Caron, Leontien CM Kremer | |
| 2010 Mar 17 | Different anthracycline derivates for reducing cardiotoxicity in cancer patients | Review | Elvira C van Dalen, Erna MC Michiels, Huib N Caron, Leontien CM Kremer | |
| 2006 Oct 18 | Different anthracycline derivates for reducing cardiotoxicity in cancer patients | Review | Elvira C van Dalen, Erna MC Michiels, Huib N Caron, Leontien CM Kremer | |
| 2004 Jan 26 | Different anthracycline derivates for reducing cardiotoxicity in cancer patients | Protocol | Elvira C van Dalen, Heleen van der Pal, Leontien C.M. Kremer | |
